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Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by neutrophil articular
infiltration, joint pain and the progressive destruction of cartilage and bone. IL-22 is a key effector molecule that
plays a critical role in autoimmune diseases. However, the function of IL-22 in the pathogenesis of RA remains
controversial. In this study, we investigated the role of IL-22 in the early phase of antigen-induced arthritis (AIA) in mice.
Methods: AIA was induced in C57BL/6, IL-22−/−, ASC−/− and IL-1R1−/− immunized mice challenged intra-articularly with
methylated bovine serum albumin (mBSA). Expression of IL-22 in synovial membranes was determined by RT-PCR.
Articular hypernociception was evaluated using an electronic von Frey. Neutrophil recruitment and histopathological
analyses were assessed in inflamed knee joint. Joint levels of inflammatory mediators and mBSA-specific IgG
concentration in the serum were measured by ELISA.
Results: The IL-22 mRNA expression and protein levels in synovial tissue were increased during the onset of AIA.
In addition, pharmacological inhibition (anti-IL-22 antibody) and genetic deficiency (IL-22−/− mice) reduced
articular pain and neutrophil migration in arthritic mice. Consistent with these findings, recombinant IL-22 joint
administration promoted articular inflammation per se in WT mice, restoring joint nociception and neutrophil
infiltration in IL-22−/− mice. Moreover, IL-22-deficient mice showed reduced synovitis (inflammatory cell influx)
and lower joint IL-1β levels, whereas the production of IL-17, MCP-1/CCL2, and KC/CXCL1 and the humoral
immune response were similar, compared with WT mice. Corroborating these results, the exogenous administration of
IL-22 into the joints induced IL-1β production in WT mice and reestablished IL-1β production in IL-22−/− mice
challenged with mBSA. Additionally, IL-1R1−/− mice showed attenuated inflammatory features induced by mBSA
or IL-22 challenge. Articular nociception and neutrophil migration induced by IL-22 were also reduced in ASC−/− mice.
Conclusions: These results suggest that IL-22 plays a pro-inflammatory/pathogenic role in the onset of AIA through an
ASC-dependent stimulation of IL-1β production.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
order that is characterized by symmetric inflammation
of the joints, which leads to the progressive destruction
of cartilage and bone [1]. The underlying cause of RA
is unknown; however, it is mediated by the persistent
production of pro-inflammatory cytokines, matrix
metalloproteinases (MMPs) and others mediators, all of
which play a key role in triggering synovial cell activation
that leads to joint destruction and, consequently, articular
pain [2, 3].
Pro-inflammatory cytokines, including tumor necrosis
factor (TNF)-α, interleukin (IL)-1β, IL-6 and, more re-
cently, IL-17, play a crucial role in the pathogenesis of arth-
ritis, increasing the recruitment of neutrophils into the
joint and driving the enhancement of chemokines and de-
gradative enzymes production [4, 5]. In addition, several
groups, including ours, have demonstrated the participa-
tion of these cytokines in the development of articular
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pain, which can act directly or indirectly on nociceptive
neurons inducing their sensitization [6–10]. Although the
pathogenic effects of these cytokines are well explored, the
contribution of IL-22 in this context is not yet fully
understood.
IL-22 is an IL-10 family cytokine member produced by
several different cell types, including T helper (Th)17
cells, natural killer (NK) cells, γδT cells, Th22 cells and
lymphoid tissue inducer-like cells (LTi) [11, 12]. IL-22
acts through a transmembrane receptor complex (IL-22R)
comprising the IL-22R1 and IL-10R2 subunits [13, 14].
This heterodimeric receptor is expressed in resident tissue
cells and is not expressed by hematopoietic immune cells
[15, 16]. Interestingly, because immune cells do not ex-
press IL-22R1, IL-22 does not directly regulate the func-
tions of these cells. This fact discriminates IL-22 from the
majority of conventional cytokines, which directly act on
hematopoietic cells. Of note, a few types of tissue cells ex-
press the IL-22R1 chain such as cells of the skin, kidney,
and liver, those from the respiratory and digestive system,
and those of the joints (synovial fibroblasts), whereas the
IL-10R2 subunit is ubiquitously expressed [15]. Thus, the
expression of the IL-22R1 chain determines whether a cell
is an IL-22 target [15, 17]. IL-22 has many functions such
as regulating inflammation and autoimmunity [18–21].
Several studies indicated that IL-22 production is in-
creased during autoimmune diseases, including rheuma-
toid arthritis [22, 23]. However, the role of this cytokine in
the onset of these diseases remains controversial. On the
one hand, there is evidence that IL-22 expression in syn-
ovial tissue is increased in patients with RA and that its
upregulation often correlates with disease activity [24, 25].
Moreover, in experimental models of arthritis, IL-22−/−
mice were less susceptible to collagen-induced arthritis
(CIA) [26]. On the other hand, there is evidence that IL-22
has an anti-inflammatory effect during CIA through an in-
creased IL-10 response, indicating that IL-22 would have
dual effects depending on the phase of the disease [27].
Taking into account these apparent contradictions in the
present study, we investigated the contribution of IL-22
and the mechanism underlying the pathogenesis of joint
inflammation during the acute phase of antigen-induced
arthritis (AIA).
Methods
Animals
The experiments were performed using male C57BL/6
wild-type (WT) mice and IL-22, IL-1R1, apoptosis-
associated speck-like protein containing a C-terminal
caspase recruitment domain (ASC) and Toll-like receptor
4 (TLR4) (all in C57BL/6 background) deficient (−/−) mice
weighing 20–25 g. All knockout mice used in this study
were co-housed with WT mice for 2 weeks prior to
immunization and throughout the period of arthritis
induction. IL-22−/− mice did not present any sign of other
phenotypes (such as gut diseases) for the duration of the
study. The mice were housed in temperature-controlled
rooms (22–25 °C) and given water and food ad libitum at
the animal facility in the Department of Pharmacology,
Ribeirão Preto Medical School, University of São Paulo,
Brazil. The mice were taken to the testing room at least 1
h before experiments and were used once. All experiments
were conducted in accordance with the prescribed
guidelines on experimental animal welfare of the National
Institutes of Health and were approved by the Ethics
Committee of the Ribeirão Preto Medical School, Univer-
sity of São Paulo.
Drugs
The following materials were obtained from the indicated
sources: recombinant murine IL-22 (rmIL-22; R&D Systems,
Minneapolis, MN, USA), anti-IL-22 antibody (α-IL-22)
(16-7222-85; eBioscience, San Diego, CA, USA), zymosan,
fucoidin, methylated bovine serum albumin (mBSA) and
complete Freund adjuvant (CFA; Sigma-Aldrich, St. Louis,
MO, USA). The drugs were diluted in sterile saline.
Induction of experimental arthritis
Antigen-induced arthritis (AIA)
The mice were immunized as previously described [28].
Briefly, the mice were sensitized with 500 μg of mBSA in
0.2 ml of an emulsion containing 0.1 ml saline and 0.1
ml CFA (1 mg/ml of Mycobacterium tuberculosis) given
by subcutaneous (s.c.) injection on day 0. The mice were
boosted with the same preparation on day 7. Sham-
immunized (SI) mice were given similar injections but
without the antigen (mBSA). Twenty-one days after the
initial injection, arthritis was induced in the immunized
animals by an intra-articular (i.a.) injection of mBSA
(30 μg/joint) or IL-22 (0.1, 0.3, 1 or 3 ng/joint) dissolved
in 10 μL of saline into the right femur-tibial joint. It is im-
portant to mention that previous reports demonstrated
that the administration of mBSA in SI mice induced ef-
fects similar to those produced by the injection of saline,
indicating that, in immunized mice, mBSA induced a spe-
cific immune response, thus excluding the possibility of
any contamination [9, 29].
Zymosan-induced arthritis (ZIA)
ZIA was induced using a previously described protocol
[30]. In brief, joint inflammation was induced by the i.a.
administration of 30 μg of zymosan (from Saccharomyces
cerevisiae) that was diluted in 10 μL of saline into the right
femur-tibial joint. Control mice were injected with 10 μL
of saline into the same joint.
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Evaluation of articular hypernociception
The articular hypernociception of the femur-tibial joint
was evaluated using a previously described method [9].
In a quiet room, the mice were placed in acrylic cages
(12 × 10 × 17 cm high) with a wire grid floor 15–30 min
before testing for environmental adaptation. Stimulations
were performed only when the animals were quiet, did
not display exploratory movements or defecation and
were not resting on their paws. In these experiments,
an electronic pressure meter, which comprises a hand-held
force transducer fitted with a polypropylene tip (IITC Inc.,
Life Science Instruments, Woodland Hills, CA, USA), was
used. For this model, a large tip (4.15 mm2) was adapted to
the probe. The investigator (blind to group allocation) was
trained to apply the tip perpendicularly to the central area
of the plantar surface of the hind paw to induce flexion of
the femur-tibial joint, followed by paw withdrawal. A grad-
ual increase in pressure was manually performed in blind
experiments. The upper limit pressure was 15 g. The elec-
tronic pressure meter apparatus automatically recorded
the intensity of the force applied when the paw was
withdrawn. The test was repeated until three subsequent
consistent measurements (i.e., the variation among these
measurements was less than 1 g) were obtained. The
flexion-elicited mechanical threshold was expressed in
grams (g).
In vivo neutrophil migration
Immunized or non-immunized mice were challenged with
mBSA, IL-22, zymosan or saline directly into the articular
cavity. At various time points after injection of the inflam-
matory stimuli, the mice were sacrificed. The articular
cavities were washed twice with 5 μL phosphate-buffered
saline (PBS) containing 1 mM ethylenediaminetetraacetic
acid (EDTA) and were then diluted to a final volume of
50 μL with PBS/EDTA to evaluate leukocyte migration
at the indicated times. The total number of leukocytes
was counted in a Neubauer chamber diluted in Turk’s
solution. Differential cell counts were determined in cyto-
centrifuge Rosenfeld-stained slices (Cytospin 4; Shandon,
Pittsburgh, PA, USA). Differential cell counts were per-
formed with a light microscope, and the results were
expressed as the number (mean ± SEM) of neutrophils
per joint cavity.
Cytokine measurements
At the indicated times after i.a. injection of the inflamma-
tory stimuli, the animals were terminally anesthetized, and
the knee joints or synovial membranes were removed and
homogenized in 500 μl or 100 μl, respectively, of
buffer-containing protease inhibitors. IL-17, IL-1β, IL-22,
monocyte chemoattractant protein-1 (MCP-1/CCL2) and
keratinocyte-derived chemokine (KC/CXCL1) concentra-
tions were measured by enzyme-linked immunosorbent
assay (ELISA) using commercial kits (DuoSet; R&D
Systems) as previously described [31]. The results are
expressed as pg/joint of each cytokine. As a control, the
concentrations of these cytokines were measured in im-
munized animals injected with saline and in SI mice
injected with mBSA.
Pharmacological treatments
In this study the following pharmacological treatments
were used: (i) C57BL/6 immunized mice were co-treated
with an antibody against IL-22 (α-IL-22, 5 μg/joint) or
control isotype antibody (α-CTL, 5 μg/joint), which was
administered simultaneously with mBSA (30 μg/joint) or
saline (10 μl) into the right femur-tibial joint, and mechan-
ical articular hypernociception was evaluated 1–7 h after
administration of the stimulus, followed by the evaluation
of neutrophil migration. (ii) WT or IL-22−/− immunized
mice were challenged i.a. with saline or mBSA (30 μg/
joint) and co-treated with a co-injection of rmIL-22
(0.3 ng/joint) or vehicle, and articular hypernociception
and neutrophil migration were evaluated 7 h following
the challenge. In another set of experiments, mBSA-
immunized WT or IL-22−/− mice were injected i.a. with
mBSA (30 μg) or saline and co-treated with a co-injection
of IL-22 (0.3 ng) or vehicle. The concentrations of IL-1β
were determined 3 h after the challenge. (iii) mBSA-
immunized mice were pretreated with fucoidin, a leukocyte
adhesion inhibitor (20 mg/kg, i.v. 15 min prior to the i.a.
injection of IL-22), and levels of IL-1β in the joint were de-
termined by ELISA 3 h after the injection of rmIL-22.
Anti-mBSA antibody titer measurement
Serum anti-mBSA antibody titers in pooled sera from
WT and IL-22−/− mice were measured by ELISA. In brief,
96-well plates were coated with 50 μl mBSA solution
(10 μg/ml, in 0.1 M phosphate buffer) overnight at 4 °C.
After that, serial dilutions of sera were added and incu-
bated overnight at 4 °C. Bound total immunoglobulin
(Ig)G and IgG2a were detected with biotin-conjugated
anti-mouse IgG and anti-mouse IgG2a, respectively (Vector
Laboratories, Burlingame, CA, USA). Finally, 50 μl
avidin-HRP (1:5000 dilution; Dako, Glostrup, Denmark)
was added to each well, and after 30 min, the plates were
washed, and the color reagent OPD (200 μg/well; Sigma-
Aldrich) was added. After 15 min, the reaction was
stopped with 1 M H2SO4 and the OD was read at 490 nm.
Reverse transcription-polymerase chain reaction (RT-PCR)
assays
IL-22 mRNA expression was measured by RT-PCR as
previously described [9]. Briefly, mice were sacrificed 3 h
after mBSA injections (i.a.), and the synovial membranes
were harvested. Total cellular RNA from synovial
membranes was extracted using the TRIzol reagent
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(Invitrogen Life Technologies Corp., Carlsbad, CA, USA)
according to the directions supplied by the manufacturer.
The purity of the total RNA was measured with a Nano-
Vue Plus spectrophotometer (GE Healthcare, Little
Chalfont, UK). The wavelength absorption ratio (260/280
nm) was between 1.8 and 2.0 for all preparations. cDNA
was produced from total RNA by reverse transcription
(Superscript II, Gibco Life Technologies, Grand Island,
NY, USA). Real-time quantitative PCR mRNA analysis
was performed on an ABI Prism 7500 Sequence Detec-
tion System using the SYBR-green fluorescence system
(Applied Biosystems, Warrington, UK) for the quantifi-
cation of amplicons. RT-PCR was performed in a 13-μL
reaction volume and carried out with the following cyc-
ling parameters: initial heating at 95 °C (10 min),
followed by 40 cycles of 94 °C (1 min), 56 °C (1 min)
and 72 °C (2 min). Melting curve analysis was performed
(65–95 °C) to verify the amplification of a single product.
Samples with more than one peak were excluded. The
data were analyzed according to the comparative cycle
threshold (CT) method. The primer pairs for mouse
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
IL-22 were as follows:
Histological analysis
Femur-tibial joints were collected 7 h after challenge
with mBSA, fixed in 10 % (vol/vol) buffered formalin and
decalcified in a solution of sodium citrate and formic acid
for 2–3 weeks. The tissues were then trimmed, dehydrated
in graded ethanol, embedded in paraffin, cut into 5-μm-
thick frontal sections and stained with hematoxylin and
eosin (H&E). Two independent observers that were
blinded to the treatment graded the extent of synovitis
(inflammatory cell influx and synovial hyperplasia). The
histological scoring system used was as follows: none
(0), mild (1), moderate (2) or severe (3) synovitis.
Statistical analysis
Data are reported as the means ± SEM and are represen-
tative of two separate experiments. Two-way ANOVA was
used to compare the groups and doses at the different
times (curves) when the hypernociceptive responses were
measured after the stimulus injection. The analyzed fac-
tors were the treatments, the time, and the time versus
treatment interaction. If there was a significant time versus
treatment interaction, one-way ANOVA followed by
Bonferroni’s t test was performed for each time. Alterna-
tively, if the responses (hypernociception, neutrophil mi-
gration, and cytokine production) were measured only
once after the stimulus injection, the differences between
responses were evaluated by one-way ANOVA followed
by Bonferroni’s t test (for three or more groups), compar-
ing all pairs of columns, or by two-tailed Student’s t test
(for two groups). P values less than 0.05 were considered
significant. Statistical analysis was performed with Graph-
Pad Prism (GraphPad Software, San Diego, CA, USA).
Results
Local production of IL-22 participates in the pathogenesis
of AIA in mice
First, it was observed that the mBSA challenge into the
femur-tibial joint of immunized mice induced an increase
in IL-22 mRNA expression in synovial tissue 3 h after
stimulus injection (Fig. 1a). Additionally, the i.a. injection of
mBSA in immunized mice also promoted an increase in
IL-22 protein levels in the synovial membrane at 7 h after
the challenge (Fig. 1b). Local (joint) treatment of mice with
a neutralizing antibody against IL-22 (injected simultan-
eously with mBSA) reduced joint nociception and neutro-
phil migration during arthritis development (Fig. 1c and d).
The local pro-inflammatory effect of IL-22 in AIA was
further confirmed because a rmIL-22 challenge into the
femur-tibial joint in mBSA-immunized mice induced a
dose- and time-dependent decrease in the mechanical
nociceptive threshold (Fig. 1e) and stimulation of neu-
trophil recruitment at 7 h after the challenge (Fig. 1f ). A
significant articular nociceptive response was observed
1 h after i.a. injections of IL-22 at all doses (0.1–3 ng),
which progressively increased for 7 h following the
challenge (Fig. 1e). An i.a. injection of IL-22 induced a
significant dose-dependent (0.1–3 ng/joint) decrease in
the nociceptive threshold (Fig. 1e) and an increase of
neutrophil migration (Fig. 1f ) when compared to mice
that were injected with saline. A dose of 1 ng per joint
of IL-22 produced a significant difference in articular
pain and neutrophil recruitment compared with doses
of 0.1 and 0.3 ng of IL-22. A dose of 3 ng/joint produced
no further effects (Fig. 1e and f). Consequently, a dose of
1 ng per joint of IL-22 was used in subsequent experi-
ments. The effects of IL-22 were reduced in SI mice when
compared with mBSA-immunized mice (data not shown).
In an attempt to exclude possible contamination with
lipopolysaccharide (LPS) in the IL-22 preparations, IL-22
was administered into the joints of TLR4−/− mice, and ar-
ticular hypernociception and neutrophil migration were
determined. It was observed that IL-22-induced articular
hypernociception and neutrophil migration were similar
in TLR4−/− mice when compared with WT mice (Figure
S1A and S1B in Additional file 1).
IL-22 forward: 5′- AGC AAA TCA GCT CAG CTC CTG- 3′;
IL-22 reverse: 5′- CTT CTT CTC GCT CAG ACG CA- 3′;
GAPDH forward: 5′- CAT CTT CTT GTG CAG TGC CA -3′;
GAPDH reverse: 5′- CGG CCA AAT CCG TTC AC-3′;
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Fig. 1 Role of IL-22 in the acute phase of AIA. a mBSA-immunized mice were challenged i.a. with 30 μg of mBSA or saline. After 3 h, synovial
membranes were collected and analyzed for IL-22 mRNA expression by PCR. The gene expression was normalized to GAPDH expression. b The
concentrations of IL-22 in the synovial membranes were determined at 1.5, 3 and 7 h after a challenge with either 30 μg of mBSA or saline in
mBSA-immunized mice. c Articular hypernociception was evaluated 1–7 h after i.a. injection with either mBSA (30 μg) or saline in mBSA-immunized
mice treated with a co-injection of IgG control (α-CTL) or α-IL-22 (5 μg/cavity) antibodies. d Neutrophil recruitment from the articular cavity 7 h after
i.a. administration of mBSA (30 μg) or saline and treatment with a co-injection of α-CTL or α-IL-22 antibodies. e and f mBSA-immunized mice were
challenged i.a. with either 0.1–3 ng of rmIL-22 or 10 μl of saline. e Articular hypernociception was evaluated over a period of 7 h. f Neutrophil
recruitment from the articular cavity 7 h after i.a. injection of either IL-22 (0.1–3 ng per joint) or saline in mBSA-immunized mice. Data are the
means ± SEM (n = 5). *P < 0.05, compared with the saline group; #P < 0.05, compared with the mBSA plus α-CTL group; and &P < 0.05, compared with
the IL-22 0.1 and 0.3 ng i.a. groups. AIA antigen-induced arthritis, GAPDH glyceraldehyde 3-phosphate dehydrogenase, i.a. intra-articular, Ig
immunoglobulin, IL interleukin, mBSA methylated bovine serum albumin, PCR polymerase chain reaction, rmIL-22 recombinant murine IL-22
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To further confirm the participation of IL-22 in the
pathophysiological mechanisms associated with AIA de-
velopment, IL-22−/− immunized mice were challenged with
i.a injection of mBSA. On the one hand, corroborating with
the pharmacological data, joint nociception and neutrophil
migration were reduced in IL-22−/− compared with WT
mice 7 h after mBSA challenge (Fig. 2a and b). On the
other hand, joint injections of exogenous rmIL-22 during
the antigen challenge were able to reestablish articular
hypernociception and neutrophil migration in IL-22−/−
mice (Fig. 2a and b).
Further exploring the participation of IL-22 in the acute
inflammatory response during AIA, the histopathological
analyses of joint tissue revealed that IL-22−/− mice showed
reduced synovitis with less cellular infiltration and the ab-
sence of synovial hyperplasia and cartilage damage when
compared with WTmice 7 h after mBSA challenge (Fig. 3a
and b). Altogether, these results suggest that local IL-22
production is required for the acute joint inflammatory re-
sponse during AIA in mice.
To verify whether the reduced local inflammatory re-
sponse in IL-22−/− mice during AIA was due to an im-
paired immunization state, anti-mBSA antibody levels in
the sera of immunized mice were determined. Interestingly,
the serum levels of antibodies against mBSA, total IgG
(Figure S2A in Additional file 2) and IgG2a (Figure S2B
in Additional file 2) were similar in immunized WT and
IL-22−/− mice (Figure S2A and B in Additional file 2).
Altogether, these findings suggest that the lower inflam-
matory response of IL-22−/− mice during AIA was not
associated with a decreased humoral immune response
to mBSA.
Next, we developed a model of zymosan-induced arth-
ritis in IL-22−/− mice to evaluate whether the reduction
of AIA in IL-22−/− mice is a specific phenotype or a con-
sequence of strain manipulation. Injection of zymosan
(i.a., 30 μg/joint) induced mechanical articular hyperno-
ciception and intense neutrophil recruitment in WT
mice that was not altered in IL-22−/− mice (Figure S3A
and B in Additional file 3). These findings argue against
IL-22−/− mice having a defect in the inflammatory re-
sponse as a consequence of genetic manipulation.
IL-22 mediates the acute inflammatory response of AIA
through the modulation of IL-1β production
To identify the possible underlying mechanisms by which
IL-22 mediates the local inflammatory response during
AIA, local cytokine and chemokine production was de-
termined in the joints of IL-22−/− mice. The injection of
mBSA into the joints in WT immunized mice increased
the local production of IL-1β, IL-17, MCP-1/CCL2, and
KC/CXCL1 at 3 h after the challenge (Fig. 4a–d, re-
spectively). Interestingly, the production of IL-1β (Fig. 4a)
was reduced in IL-22−/− mice during the early phase of
AIA, whereas the production of IL-17, MCP-1/CCL2 and
KC/CXCL1 did not differ from WT mice (Fig. 4b–d).
To confirm the participation of IL-1β in the inflamma-
tory response during the early phase of AIA, IL-1R1−/−
mice were immunized, followed by i.a. injections of mBSA.
First, mBSA challenge into the femur-tibial joint of WT
mice produced a time-dependent increase in the levels of
IL-1β in the joint tissues (Fig. 5a). Additionally, joint noci-
ception and neutrophil migration during AIA were signifi-
cantly diminished in IL-1R1−/− mice after mBSA challenge
Fig. 2 IL-22 is required for articular hypernociception and neutrophil migration in AIA. mBSA-immunized wild-type (WT) mice or IL-22−/− mice
were challenged i.a. with saline or mBSA (30 μg) and treated with a co-injection of rmIL-22 (0.3 ng) or vehicle. Articular hypernociception (a) and
neutrophil migration (b) were evaluated 7 h following the challenge. Data are the means ± SEM (n = 5). *P < 0.05, compared with the saline group;
#P < 0.05, compared with the WT mBSA group; and &P < 0.05 compared with the IL-22−/− mBSA group. (−/−) deficient, AIA antigen-induced arthritis, i.a.
intra-articular, IL interleukin, mBSA methylated bovine serum albumin, rmIL-22 recombinant murine IL-22
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compared with WT mice (Fig. 5b and c). The local produc-
tion of IL-1β, KC/CXCL and MCP-1/CCL2, which were
induced by i.a. administration of mBSA in WT immunized
mice, was not altered in IL-1R1−/− mice (Fig. 5d–f).
According to the hypothesis that IL-22 participates in
the joint inflammatory response during AIA through the
stimulation of IL-1β production, the injection of IL-22
into the joints of mBSA-immunized mice significantly
increased the levels of IL-1β in a time-dependent manner
(Fig. 6a). Moreover, the injection of exogenous rmIL-22
into the joints of IL-22−/− mice reestablished the levels
of IL-1β compared with the levels of WT mice during
the mBSA challenge (Fig. 6b). In addition, joint hyper-
nociception and neutrophil recruitment induced by i.a.
injection of rmIL-22 were reduced in IL-1R1−/− mice
(Fig. 6c and d). Taken together, these data indicate that
Fig. 3 Lower histopathological score in IL-22-deficient mice than in WT mice with AIA. Histological analysis of knee joints of WT and IL-22−/−
immunized mice 7 h after mBSA (30 μg/i.a.) challenge. a Hematoxylin and eosin (H&E)-stained representative histological section (upper panel:
magnification, 5×; and lower panel: higher magnification, 20×). b AIA severity was measured by the histological score for synovitis. The histological
scoring system used was as follows: none (0), mild (1), moderate (2) or severe (3) synovitis. Data represent the mean ± SEM (n = 6), *P < 0.05, compared
with the saline group; #P < 0.05, compared with the WT mBSA group. (−/−) deficient, AIA antigen-induced arthritis, i.a. intra-articular, IL interleukin, mBSA
methylated bovine serum albumin, WT wild-type
Fig. 4 IL-22 differentially regulates local pro-inflammatory cytokines and chemokines in the early phase of AIA. The concentrations of IL-1β (a),
IL-17 (b), MCP-1/CCL2 (c) and KC/CXCL1 (d) in the knee joint injected with mBSA (30 μg) or saline in WT and IL-22−/− mBSA-immunized mice
were determined at 3 h after challenge. The levels of cytokines and chemokines were evaluated by ELISA. Data are the means ± SEM (n = 5).
*P < 0.05, compared with the saline group; and #P < 0.05, compared with the mBSA group. (−/−) deficient, AIA antigen-induced arthritis, ELISA
enzyme-linked immunosorbent assay, IL interleukin, KC/CXCL1 keratinocyte-derived chemokine, mBSA methylated bovine serum albumin,
MCP-1/CCL2 monocyte chemoattractant protein-1, WT wild-type
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IL-22 might have a modulatory role in the production
of IL-1β during the early phase of AIA that accounts
for the local inflammatory response.
In an attempt to evaluate the mechanism involved in
the production of IL-1β induced by IL-22 during the
acute phase of AIA, we first pretreated WT immunized
mice with fucoidin (a leukocyte adhesion inhibitor) [32],
and 3 h after a challenge with rmIL-22 (1 ng per joint),
the levels of IL-1β were determined by ELISA. Interestingly,
the joint production of IL-1β induced by IL-22 was signifi-
cantly increased in WT immunized mice pretreated
with fucoidin when compared with the vehicle group
(Figure S4A in Additional file 4), suggesting that neutrophils
that are recruited to the joint after IL-22 administration are
Fig. 5 Participation of IL-1β in the development of AIA. a The concentrations of IL-1β in the knee joint injected with either 30 μg of mBSA or
saline in mBSA-immunized mice were determined at 1, 3, 5 and 7 h after challenge. b Articular hypernociception was evaluated 1–7 h after i.a.
injection with either mBSA (30 μg) or saline in mBSA-immunized WT or IL-1R1−/− mice. c Neutrophil recruitment toward the articular cavity 7
h after i.a. administration of mBSA (30 μg) or saline in mBSA-immunized WT or IL-1R1−/− mice. d-f The concentrations of IL-1β (d), KC/CXCL1
(e) and MCP-1/CCL2 (f) in the knee joint injected with mBSA (30 μg) or saline in WT and IL-1R1−/− mBSA-immunized mice were determined at
3 h after challenge. Data are the means ± SEM (n = 5). *P < 0.05, compared with the saline group; and #P < 0.05, compared with the WT mBSA
group. (−/−) deficient, AIA antigen-induced arthritis, ELISA enzyme-linked immunosorbent assay, IL interleukin, KC/CXCL1 keratinocyte-derived
chemokine, mBSA methylated bovine serum albumin, MCP-1/CCL2 monocyte chemoattractant protein-1, WT wild-type
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not the main source of IL-1β. By further investigating the
mechanisms involved in the production of IL-1β triggered
by IL-22, it was observed that articular hypernociception
and neutrophil migration induced by i.a. injections of IL-22
in WT immunized mice were significantly diminished in
ASC−/− immunized mice 7 h after the challenge (Figure S4B
and C in Additional file 4). These results suggest (although
indirectly) that IL-22 stimulation of joint IL-1β production
in the acute phase of AIA might be dependent on ASC.
Discussion
It is well accepted that the presence of various pro-
inflammatory cytokines in the joint environment con-
tributes to the pathophysiology of autoimmune arthritis
[33]. In the last decade, IL-22, a cytokine with pleio-
tropic effects, has been implicated in joint pathology
during inflammatory arthritis [22, 23]. For instance, the
presence of IL-22 and IL-22R1 in synovial tissue [22, 34]
and elevated levels of this cytokine in the serum of RA pa-
tients have been demonstrated [35, 36]. However, the role
of IL-22 in the pathophysiology of RA remains under de-
bate. In fact, experimental evidence presents contradictory
effects (protective versus pathogenic) for IL-22 in the gen-
esis of arthritis [26, 27, 37]. Herein, we demonstrated that
IL-22 is pathogenic in the early phase of AIA in mice, me-
diating neutrophil migration and pain. IL-22 seems to be
important in the induction of the local production of
IL-1β, which is an important pro-arthritic cytokine that
mediates leukocyte recruitment to the joint as well as
the joint pain.
Previous reports have observed an increase in IL-22
expression in experimental models of arthritis in mice.
Indeed, Geboes and collaborators (2009) [26] first dem-
onstrated that IL-22 and IL-22R1 levels were elevated in
the serum, lymphoid tissue and others tissues in immu-
nized mice during collagen-induced arthritis (CIA). In
addition, in the experimental model of spontaneous
arthritis observed in IL-1 receptor antagonist (Ra) −/−
mice, the level of IL-22 was shown to be upregulated in
inflamed synovial tissue [38]. Moreover, CD4+T cells iso-
lated from arthritic joints and splenocytes express IL-22
after the induction of AIA, suggesting the possible in-
volvement of IL-22 in this model of arthritis [39, 40]. In
further support of this suggestion, in our experiments,
we observed that mRNA expression and protein levels
of IL-22 in the synovial membrane increased during
the onset of AIA. Moreover, the results obtained using
pharmacological (antibody against IL-22) and genetic
(IL-22−/− mice) inhibition of this cytokine indicate a
pro-inflammatory role of IL-22 in the earlier phase of
AIA. Supporting these findings, the direct administration
of recombinant murine IL-22 into the joints recapitu-
lates the clinical (pain enhancement) and morphological
(neutrophil migration) characteristics of arthritis. In agree-
ment with our results, treatment with anti-IL-22 reduced
inflammation and bone erosion in IL-1-driven arthritis
Fig. 6 IL-1β mediates the pro-inflammatory effects of IL-22 in AIA. a mBSA-immunized mice were injected i.a. with IL-22 (1 ng) or saline and the
concentrations of IL-1β were determined at 0.5, 1, 3 and 6 h after challenge. b mBSA-immunized WT or IL-22−/− mice were challenged i.a. with
mBSA (30 μg) or saline and treated with a co-injection of IL-22 (0.3 ng) or vehicle. The concentrations of IL-1β were determined 3 h after challenge.
c and d mBSA-immunized WT or IL-1R1−/− mice were challenged i.a. with IL-22 (1 ng per joint) or saline and articular hypernociception (c)
and neutrophil migration (d) were evaluated 7 h following the challenge. Data are expressed as the means ± SEM (n = 5). *P < 0.05, compared
with the saline group; #P < 0.05 compared the WT mBSA or WT IL-22 group; and &P < 0.05 compared with the IL-22−/− mBSA group. (−/−), deficient, AIA
antigen-induced arthritis, i.a. intra-articular, IL interleukin, mBSA methylated bovine serum albumin, WT wild-type
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[38]. Furthermore, neutralization of IL-22 after the on-
set of CIA diminished the severity of arthritis [37].
On the other hand, a recent report showed that IL-22−/−
mice present no differences in knee swelling and macro-
scopic inflammation scores (evaluated by redness) com-
pared to WT mice 7 days after AIA induction [41]. This
lack of effect can be explained by the intense amount of
stimuli (mBSA- 60 μg/i.a.) administered in the joint com-
pared to that used in our study (mBSA- 30 μg/i.a.). Fur-
thermore, the time of evaluation of the parameters was
also different. While we analyzed the role of IL-22 in the
acute phase of AIA (7 h after induction), van Hamburg
and colleagues (2013) evaluated the inflammatory parame-
ters 7 days after AIA induction. Thus, we could not ex-
clude that IL-22 might have a different role in acute and
late phases of the disease. In fact, there is evidence that
IL-22 has a dual role in inflammatory diseases [42, 43].
The experimental model of antigen (mBSA)-induced
arthritis is a suitable and reproducible experimental sys-
tem that exhibits several features with histopathological
findings similar to those observed in human RA [28].
The adaptive immune response in AIA is dependent on
antigen-specific CD4+ T cells and their derived mediators
and, to a lesser extent, is mediated by serum antibodies
[44, 45]. Interestingly, the titers of anti-mBSA antibodies
were similar in WTand IL-22−/− mice. This is noteworthy,
because IL-22−/− mice exhibit higher levels of collagen
type II-specific and total IgG antibodies during CIA [26].
Although anti-mBSA antibodies have been detected in
AIA, it is important to mention that this RA model is
less dependent on the humoral response [28]. Indeed,
B-lymphocyte-deficient μMT/μMT mice (which lack ma-
ture B lymphocytes and do not produce IgM or IgG anti-
bodies) develop AIA that is similar to that developed in
WT mice, suggesting that B cells do not participate, at
least during the acute phase of AIA [46]. Besides the
humoral response, it was demonstrated that the prolif-
erative response, T cell phenotype and cytokine levels
in the supernatant of lymph node cells were similar be-
tween arthritic IL-22−/− and WT mice [41]. Taken together,
these pieces of evidence indicate that the lower inflam-
matory response of IL-22−/− mice during AIA was not
associated with a decreased humoral or cellular immune
response to mBSA.
Previous reports have shown that mBSA injection in-
duces the production of several cytokines (IL-17, IL-1β)
and chemokines (CXCL1/KC) during antigen-induced
inflammation [9, 29, 47]. Interestingly, our findings dem-
onstrate that only IL-1β production was decreased by
the genetic inhibition of IL-22, indicating that the patho-
genic role of IL-22 during AIA onset could be mediated
through IL-1β. In accordance with our results, it was
demonstrated that the increased IL-1β expression in
synovial tissues during CIA was diminished in IL-22−/−
mice [26]. In addition, in an experimental model of
skin inflammation, the levels of IL-1β were decreased
in IL-22−/− mice [48]. Nevertheless, we cannot exclude the
involvement of other mediators in this effect of IL-22 in
the early phase of AIA.
The participation of IL-1β was also observed in other
models of articular inflammation. In fact, it was shown
that IL-1β mediates inflammation and dysfunction of the
joint induced by the injection of monosodium urate (MSU)
crystals into the knee in an experimental model of gout
[49]. Additionally, in the spontaneous inflammatory arth-
ritis model of K/BxN T cell receptor-transgenic mice, IL-1β
is absolutely necessary for joint inflammation [50]. Our re-
sults indicate that IL-1β mediates the induction of inflam-
matory events (neutrophil migration and pain) in AIA,
which is not dependent on the modulation of the produc-
tion of cytokines and chemokines. Thus, it is possible that
the pro-inflammatory effects of IL-1β that are observed
during AIA might be directly connected to pain induction
as a consequence of the stimulation of the production of
prostaglandins (which are important in the sensitization of
primary nociceptive fibers) and on neutrophil migration,
since it can modulate endothelial adhesion molecules
[51–53]. In addition, it is important to note that IL-1β
also has direct and indirect effects in the nociceptive
neurons, inducing their sensitization and neutrophil migra-
tion [8, 54–56]. In this context, our group demonstrated
that IL-1β mediates neutrophil migration induced by
several cytokines, including IL-17, during AIA [9]. In
the present study, no difference in the production of
IL-17A was observed between IL-22−/− and WT mice,
suggesting that the pro-arthritic role of IL-22 appears
to be independent of IL-17 release in the joint. It is im-
portant to propose that IL-17 can induce IL-22 or that
these cytokines may act together to mediate the patho-
genesis of AIA. For instance, the interdependence of
IL-17 and IL-22 in other models of experimental arth-
ritis has been suggested [38, 57]. Furthermore, the correl-
ation of IL-17 and IL-22 was also observed in patients
with arthritis [34]. Interestingly, the synergistic effect of
these cytokines has already been demonstrated in other
models of inflammation. Indeed, in an experimental
model of airway inflammation, it was suggested that
IL-22 can act cooperatively with IL-17A, which contrib-
utes to the pathological role of IL-22 in the lung [42, 43].
Concerning the mechanism involved in the IL-22-
induced production of IL-1β, our data indicate that it is
not dependent on recruited neutrophils, but it may be
dependent on resident cells. Another important observa-
tion is that the pro-inflammatory role of IL-22 in joint
inflammation appears to be dependent on ASC. In ac-
cordance, it was demonstrated that the adapter molecule
ASC mediates the pro-inflammatory response in AIA
and production of IL-1β [58]. However, it appears that
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the role of ASC in AIA development does not require
NLRP3/caspase-1 and NLRC4/caspase-1 inflammasomes
[58]. Thus, further studies are necessary to elucidate the
relationship between IL-22 and ASC in the development
of AIA.
Conclusions
In summary, the present data provides evidence that
joint IL-22 is pathogenic during the onset of antigen-
induced arthritis in mice. Our findings also suggest that
the pro-inflammatory role of IL-22 in the physiopathol-
ogy of arthritis is dependent on the modulation of IL-1β
production in the joint, which may be dependent on ASC.
Therefore, it seems that IL-22 is a possible therapeutic
target in the initial phase of RA, controlling the various
symptoms present in arthritis.
Additional files
Additional file 1: Figure S1. Pro-inflammatory effects of IL-22 in TLR4−/−
mice are similar to WT mice. (A and B) WT or TLR4−/− mice were challenged
i.a. with IL-22 (1 ng per joint) or saline, and articular hypernociception (A)
and neutrophil migration (B) were evaluated 7 h after the challenge. Data
are presented as the means ± SEM (n = 5). *P < 0.05, compared with
the saline group. (TIFF 1072 kb)
Additional file 2: Figure S2. Immunoglobulin production of WT and
IL-22−/− mice. Levels of total IgG (A) and IgG2a (B) antibodies against
mBSA in the sera of WT and IL-22−/− mBSA-immunized mice. Data are
the means ± SEM (n = 5). (TIFF 1185 kb)
Additional file 3: Figure S3. Role of IL-22 in zymosan-induced arthritis.
(A and B) WT or IL-22−/− mice were challenged i.a. with zymosan (30 μg
per joint) or saline and articular hypernociception (A) and neutrophil
migration (B) were evaluated 7 h after the challenge. Data are presented as
the means ± SEM (n = 5). *P < 0.05, compared with the saline group.
(TIFF 1105 kb)
Additional file 4: Figure S4. The inflammasome adapter ASC participates
in articular hypernociception and neutrophil migration that are induced by
IL-22 during AIA. (A) The concentrations of IL-1β in the knee joint injected
with 1 ng of IL-22 or saline and pretreated with fucoidin (20 mg/kg, i.v. 15
min before stimuli injection) in mBSA-immunized mice were determined 3 h
after the challenge. (B) Articular hypernociception was evaluated 1–7 h after
i.a. injection with either IL-22 (1 ng per joint) or saline in mBSA-immunized
WT or ASC−/− mice. (C) Neutrophil recruitment toward the articular cavity 7 h
after i.a. administration of IL-22 (1 ng) or saline in mBSA-immunized WT or
ASC−/− mice. Data are presented as the means ± SEM (n = 5). *P < 0.05,
compared with the saline group; and #P < 0.05, compared with the vehicle
(−)/WT IL-22 groups. (TIFF 930 kb)
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